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Abstract 
Homocysteine is produced physiologically in all cells, and is present in plasma of healthy 
individuals (plasma  [HCy]: 3-10µM). While rare genetic mutations (CBS, MTHFR) cause 
severe hyperhomocysteinemia ( [HCy]: 100-200µM), mild-moderate hyperhomocysteinemia 
( [HCy]: 10-100µM) is common in older people, and is an independent risk factor for stroke 
and cognitive impairment. As B-vitamin supplementation (B6, B12 and folate) has well-
validated homocysteine-lowering efficacy, this may be a readily-modifiable risk factor in 
vascular contributions to cognitive impairment and dementia (VCID).  
Here we review the biochemical and cellular actions of HCy related to VCID. Neuronal 
actions of HCy were at concentrations above the clinically-relevant range. Effects of HCy 
<100 µM were primarily vascular, including myocyte proliferation, vessel wall fibrosis, 
impaired nitric oxide signalling, superoxide generation and pro-coagulant actions. HCy-
lowering clinical trials relevant to VCID are discussed. Extensive clinical and preclinical data 
support Hcy as a mediator for VCID. In our view further trails of combined B-vitamin 
supplementation are called for, incorporating lessons from previous trails and from recent 
experimental work. To maximise likelihood of treatment effect, a future trial should: supply a 
high-dose, combination supplement (B6, B12 and folate); target the at-risk age range; target 
cohorts with low baseline B-vitamin status.  
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1. Introduction 
1.1 Homocysteine and vascular contributions to cognitive impairment and dementia (VCID).  
Brain vascular lesions contribute to dementing illness in the form of vascular dementia, 
vascular factors exacerbating Alzheimer’s disease (AD), and other cognitive impairment 
states where diagnostic criteria for dementia are unmet [81,87]. This considerable burden of 
dementia-related illness is covered by the concept of vascular contributions to cognitive 
impairment and dementia (VCID) [35,87,107]. The most common cause of VCID is thought 
to be a common brain vascular pathology called cerebral small vessel disease (SVD) 
[28,82,87,92].  
 
Homocysteine (HCy) is a thiol-containing non-essential amino acid (Table 1) that is produced 
in all cells, as a product of normal folate and methionine metabolism. Elevated plasma 
homocysteine is referred to as hyperhomocysteinemia (HHCy). HHCy is a robust and 
independent risk factor for stroke [44,48,61,97,98] and for cognitive impairment [101,105] 
and is associated with pathologically-confirmed AD [16]. HHCy is associated with an 
increased rate of hippocampal atrophy [16] and with accelerated cognitive decline in AD 
patients [88] and is now accepted as a risk factor for AD [6]. Plasma HCy concentration is 
strongly associated with hippocampal atrophy, white matter lesions and lacunar infarcts in 
cross-sectional studies [32,61,117,123]. The association with hippocampal atrophy appears to 
be independent of amyloid pathology [14]. White matter lesions reflect vascular damage [92] 
and it is therefore notable that white matter changes are associated with HHCy [47,49,64,94] 
and with low vitamin B12 levels [21] and low folate [51,100]. Evidence supporting a causal 
relationship between HHCy and cerebrovascular injury includes: i) independent, graded 
association of HHCy with stroke in prospective and retrospective clinical studies [48,61]; ii)  
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genetic association studies of genes regulating HCy metabolism, using Mendelian 
randomisation [9];  iii) HHCy-induced lesions in experimental animals [4,68,108,111]. 
Dietary supplementation with the appropriate B-vitamins (B6, B12 and folate) clearly 
ameliorates HHCy. Thus HHCy may be a modifiable risk factor in VCID. 
 
1.2 Biochemistry of homocysteine.  
Rare genetic mutations in folate and methionine metabolizing enzymes (CBS, MTHFR) 
produce severe HHCy (plasma HCy in excess of 100 µM; up to ~500 µM). Plasma HCy can 
also be elevated by smoking, aging, deficiency in folate or vitamin B12, or renal failure. 
Clinical mild-moderate HHCy is common, especially in older people. Mild-moderate HHCy 
is various defined, with lower limits ranging from 10-15 µM and upper limits 30-100 µM.  
Plasma HCy is derived from cellular export via cysteine and folate transporters [50,56] and 
circulating HCy levels are maintained at relatively low levels by ongoing enzymatic 
conversion to either methionine or cysteine (see Figure 1). Plasma total HCy concentration in 
healthy individuals is typically in the range 5-10 µmoles/litre (µM). Previous detailed 
reviews are available on HCy biochemistry [52,115]. For the purposes of this review 
(including data from biochemical assays, cell cultures, experimental animals and clinical 
populations) we have defined mild-moderate HHCy by homocysteine concentrations in the 
range 10-100 µM, and severe HHCy as >100 µM. 
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Table 1. Homocysteine and related molecular species 
Molecule Structure Formation 
Homocysteine, HCy 
 
Formed in normal 
cell metabolism of  
folate and  
methionine 
Homocystine  
 
 
 
Disulphide bonded 
dimerization of 
HCy 
Homocysteine 
thiolactone 
(shown as 
hydrochloride) 
  
Condensation of the 
SH and carboxylic 
acid groups of HCy 
Homocysteic acid, 
HCA 
(-SO3H dissociates to 
form homocysteate 
anion, -SO3
-
) 
  
Uncertain, possibly 
oxidation  of HCy 
Abbreviations. HCy, homocysteine. HCA, homocysteic acid. 
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1.3 Homocysteine and cerebral small vessel disease (SVD).  
SVD is a vessel pathology that affects small penetrating arteries (up to 400 µm outer 
diameter) in deep subcortical brain regions, primarily the basal ganglia and deep white matter 
[31,77]. It is characterised neuropathologically by fibrous, hyaline thickening of vessel wall, 
loss of myocytes, and relative preservation of endothelium [40,90]. SVD is common in brains 
of older people, and is a prevalent cause of microinfarcts and lacunes, lacunar stroke, and 
diffuse white matter lesions (“leukoaraiosis”) [87,90,92]. Further, neuroimaging [28,114,116] 
and neuropathology [30,31,104]  data suggest that SVD is also the most common cause of 
VCID[87,90,92]. While increasing age and hypertension are risk factors for SVD, the 
pathogenesis of SVD is not well understood [34,90].  
Multiple studies have shown that mild-moderate HHCy is a risk factor for SVD 
[32,44,45,61,61,62,117,123]. In case-control studies HHCy was positively-associated with 
SVD severity, with highest plasma total HCy concentration (plasma [HCy]; average 20 μM) 
in patients with confluent leukoaraiosis on MRI scans, indicative of more severe SVD 
[44,61]. The association between SVD and HCy was markedly attenuated after controlling 
for circulating markers of endothelial dysfunction, suggesting a possible endothelial 
mechanism for the HHCy-SVD association [44]. 
 
2. Cellular actions of HCy  
Here we review the actions of HCy at the molecular and cellular level with particular 
reference to brain cells, specifically neurones and vascular cells. Several reported actions 
occur at HCy concentrations below 100 µM, within the range of mild-moderate clinical 
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HHCy, thus direct actions of HCy in vivo on neurones, vascular endothelial cells and VSMC 
in vivo appear likely. 
 
2.1 Effects of HCy on brain neurones 
We carried out a systematic review of concentration dependence of the actions of HCy in 
brain cells (results shown in Table 2). We searched PubMed (on 12th June 2015) for articles 
in English containing the terms: (brain OR cerebr*) AND (homocyst*) AND (potency OR 
half-maximal OR IC50 OR EC50 OR ED50 OR affinity). This yielded 109 results. Abstracts 
were viewed by two independent reviewers (NY, AHH) and 41 were discarded by consensus 
(not relevant, no quantitative data, or not primary data source). Of the 68 retained, on viewing 
the full text data were extracted from all where quantitative data were given on the potency of 
homocysteine actions (Table 2) [2,3,25,27,37,38,46,54,75]. Quantitative data were also 
extracted on the actions of HCA (see Supplementary table S1).   
 
Table 2. Effects of HCy on brain neurones and glial cells  
Effects observed 
Effective 
concentration  
Cell or tissue Species Reference 
Neurite loss and size 
reduction 
>100 M 
Mesencephalic 
tegmental neurons  
Rat 
Heider et al. 
(2004) [46] 
Inhibition of neural 
network activity 
400 M 
Embryonic 
neocortical neurons 
Rat 
Gortz et al. 
(2004) [37] 
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Lipid peroxidation 100 - 1000 M Synaptosomes Rat 
Jara-Parado et al. 
(2003)[54] 
Inhibition of 
glutamine uptake  
2 mM 
Cerebral neuronal 
non-synaptic 
mitochondria 
Rat 
Albrecht et al. 
(2000)[2] 
PAG inhibition 2 mM 
Cerebral neuronal 
non-synaptic 
mitochondria 
Rat 
Albrecht et al. 
(2000)[2] 
L-glutamate 
transporter 
inhibition 
1000 M 
Synaptosomes, from 
pre-frontal cortex 
Mouse 
Griffiths et al. 
(1989)[38] 
GABAA receptor 
binding  
Ki(apparent) :  
>10 mM  
Synaptic membranes Cow 
Egubta & 
Griffiths (1987) 
[25] 
Inhibition of high 
affinity GABA 
uptake  
IC50 >5 mM 
Synaptosomes  
[whole brain] 
Rat 
Allen et al. 
(1986) [3] 
Inhibition of high 
affinity taurine 
uptake 
IC50: 2.8 mM 
Synaptosomes  
[whole brain] 
Rat 
Allen et al. 
(1986)[3] 
Inhibition of high 
affinity taurine 
IC50: 4.8 mM 
Astrocytes from 
cerebral cortex 
Rat 
Allen et al. 
(1986)[3] 
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uptake 
Inhibition of MMP-
2 activity 
IC50: 727 M 
Brain tissue 
homogenate 
Pig 
Emara & Cheung 
(2006)[27] 
Inhibition of MMP-
9 activity 
IC50: 2.35 mM 
Brain tissue 
homogenate 
Pig 
Emara & Cheung 
(2006)[27] 
Inhibition of 
kynurenic acid  
production 
IC50: 6.4 mM  Cortical neurons Rat 
Luchowska  et 
al. (2005)[75] 
Abbreviations. MMP, matrix metalloproteinase; PAG, Phosphate-activated glutaminase. 
 
Neurotoxicity and morphological changes. Incubation of mesencephalic tegmental neurons 
from rats with HCy (100M) for 48 hours produced morphological changes in the neurites of 
the tyrosine hydroxylase positive neurons (assumed to be dopaminergic)[46]. Fewer and 
shorter neurites were observed, although there were no significant effects on cell numbers 
[46]. This suggests that HCy exhibits a mild toxicity towards these dopaminergic neurons at 
a concentration of 100M. In vivo injection of HCy into the left ventricle produced dose-
dependent neuronal loss [124], with marked neuronal loss. These effects may be mediated by 
the NMDA and metabotropic glutamate receptors, as co-administration with antagonists of 
these receptors attenuated the neurotoxic effects of HCy [124]. 
Neural network activity suppression. HCY reduced neural network activity in spontaneously 
active embryonic rat cortical neurons (as measured by basal spontaneous spike rate). The IC50 
for HCy (401M) was above the range for severe HHCy, so the authors concluded that these 
12 
 
effects were not clinically relevant. Homocysteate, by contrast, had an IC50 of 1.3M. 
Homocysteate is often found to be elevated in patients with HHCy [37] and HCA may be a 
clinically relevant species.  
Lipid peroxidation. HCy (100-1000M) increased lipid peroxidation in rat brain 
synaptosomes in a concentration-dependent manner [54]. This action was prevented by an 
NMDA receptor antagonist [54] supporting a glutamate receptor dependent pathway for 
HCy-mediated neuronal damage.  
 
Several other cellular actions of HCy are reported, with effective concentrations in the 
millimolar range, (Table 2). These are unlikely to be relevant to clinical HHCy. 
Homocysteate and Homocysteic acid. The physiological metabolic pathways of HCA (see 
Table 1 for structure) are relatively little known. There is evidence that HCy may be oxidised 
to form HCA within brain and other tissues [37]. Homocysteate has neurotoxic effects, 
independent of HCy [37,46]. These appear to be due to NMDA and metabotropic glutamate 
receptor-dependent excitotoxicity (see  Supplementary table S1)[26,36,93,96]. HCA is 
clearly more potent than HCy in some cellular actions [37,38,46]. While HCA/homocysteate 
may participate in some of the cytotoxic processes observed in HHCy, native HCA levels 
appear to be low.  
 
2.2 Effects of HCy on vascular cells 
Cell damaging effects of HCy on blood vessels have been suggested for many years. Mild-
moderate HHCy could directly cause cell damage in vivo, or could represent a secondary 
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event or biomarker of a pathological process. The salient cellular actions of HCy at clinically 
relevant concentrations are listed in Table 3 and are discussed below. 
The effects reported at extracellular HCy concentrations below 100 µM suggest that direct 
HCy cytotoxicity may be relevant in vivo. We note with caution that there is little 
information on the clinically relevant range of intracellular HCy concentrations (in 
physiological conditions, approximately 100 µM). Amino acid transporters are present in 
vascular smooth muscle cells and endothelial cells, with high affinity for HCy (KM 40-100 
µM)[56]. 
 
Table 3. HCy effects in vascular cells  
 Effective 
concentration 
Cell type Species References 
In vascular smooth muscle cells 
Increased cell 
proliferation 
50 -100 µM Thoracic aortic 
VSMC 
Chick  Dalton et al. 1997 
[17] 
Increased protein 
kinase C activity 
 
3 -100 µM Thoracic and 
abdominal aorta 
VSMC  
Chick  Dalton et al. 1997 
[17] 
Increased ERK2 
activity 
 
0.1-100 µM, 
EC50 0.5 µM 
Thoracic and 
abdominal aorta 
VSMC  
Chick  Brown et al. 
1998[7] 
Increased CTGF 
release, Collagen I 
50-500 µM Umbilical vein 
VSMC 
Human Liu et al. 
2008[73] Majors 
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and fibronectin 
synthesis 
et al. 1997[76] 
Lysyl oxidase 
inhibition (by HCy 
lactone) 
5 – 50 µM,  Ki 
20 µM  
Whole aorta Calf Liu et al. 1997 
[72] 
In endothelial cells 
Reduced cell 
proliferation 
 
10 – 50 µM,   
EC50 10-20 µM 
HUVEC Human Wang et al. 
1997[119] 
Downregulation of 
cyclin A 
50 µM HUVEC Human Jamaluddin et al. 
2007 [53] 
Inhibition of 
endothelial NOS 
50 – 200 µM Thoracic aorta 
endothelial cells 
Human 
& 
Mouse 
Jiang et al. 
2005[57] 
Inhibition of 
endothelial-
dependent 
vasodilatation 
10 – 100 µM,   
EC50 10 µM 
Coronary artery 
endothelial cells 
Pig Chen et al. 2002 
[11] 
Increased 
superoxide 
formation 
30 -1000 µM Aortic 
endothelial cells 
Pig Lang et al. 2000 
[67] 
Increased release 
of MMP-9, loss of 
Integrin-1 
12 - 40 µM,  
EC50 20 µM 
Cerebral 
microvessel 
endothelial cells 
Mouse Shastry & Tyagi 
2004[103] 
Reduced binding 10 µM Aortic Pig Nishinaga et al. 
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of anti-thrombin 
III 
endothelial cells 1992 [86] 
Other actions 
Increased MCP-1, 
IL-6 release 
 
10 -1000 µM, 
EC50 30 µM 
Aortic adventitial 
fibroblasts  
Rat Liu et al.  
2012[74] 
Cell 
transformation of 
fibroblasts to  
myo-fibroblasts 
10-100 µM Aortic adventitial 
fibroblasts  
Rat Liu et al. 
2012[74] 
Reduced platelet-
fibrinogen binding 
1 - 10 µM Whole blood  Human Riba et al. 
2004[95] 
Reduced ApoA-
fibrin binding  
8 - 2000 µM,  
EC50 ~ 100 µM 
Fresh plasma Human Harpel et al. 1992 
[43] 
Increased MCP-1, 
IL-8 release from 
blood monocytes 
10 -1000 µM,  
EC50 10-30 µM 
Whole blood  Human Zeng et al. 2003 
[125] 
Abbreviations.  ApoA, apolipoprotein-A. CTGF, connective tissue-derived growth factor. 
ERK2, Extracellular signal-regulated kinase. HUVEC, human umbilical vein endothelial 
cells. IL-6, -8, interleukin-6, -8. MCP-1, monocyte chemotactic protein-1. MMP-9, matrix 
metalloproteinase-9. NOS, nitric oxide synthase. VSMC, vascular smooth muscle cells. 
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2.2.1 Vascular smooth muscle cells 
Cell proliferation.  Moderate concentrations of HCy (10-100 μM) enhanced proliferation of 
vascular smooth muscle cells (VSMC) in primary cultures [17,76]. In VSMC cultured from 
embryonic thoracic aorta, acute HCy-induced cell proliferation was associated with induction 
of c-fos and c-myb, and translocation of protein kinase C (PKC) to the plasma membrane 
[17]. In agreement with a PKC-dependent mechanism, HCy concentrations as low as 3 µM 
(range 3-100 µM) stimulated diacylglycerol synthesis in these cells [17].  The growth-related 
MAP kinase ERK2 was also rapidly activated by very low concentrations of HCy (EC50 0.5 
µM) in aortic VSMC cultured from chick embryos [7]. How this action relates to normal 
adult physiology (with ambient plasma HCy well above this concentration) is unclear. 
Mitogenic actions of acute HCy treatment were seen in myocyte cultures derived from aorta 
of adult animals, but only as higher concentrations (500-1000 µM)[112,113]. These agree 
with earlier in vivo studies in nonhuman primates undergoing chronic intravascular infusion 
with  HCy [42]. In these animals steady state plasma HCy of 160 µM produced intimal 
lesions with endothelial cell loss and myointimal cell proliferation, resembling 
arteriosclerosis [42]. The cell proliferative effect of HCy is clearly not a generalized 
response, as HCy suppresses cell proliferation in endothelial cells, (see 2.2.2 below). HCy 
may also influence cell fate. HCy (10-100 µM) treatment of adventitial fibroblasts cultured 
from rat aorta stimulated transformation to myofibroblast-like phenotype (expression of the 
myocyte-associated proteins smooth muscle actin and SM22α) [74]. 
Fibrosis and collagenosis. HCy treatment potently increased collagen synthesis in smooth 
muscle cells in vitro (over a concentration range 50 - 500 µM) [76]. In accord with a pro-
fibrotic action, treatment of human VSMC cultures with a moderate concentration of HCy 
(50 µM) increased expression of the pro-fibrotic growth factor CTGF, collagen type I, and 
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fibronectin [73]. In accord with effects of HCy on vessel fibrosis, HCy lactone (see Table 1)  
irreversibly inhibited lysyl oxidase (Ki 21 µM) [72]. This enzyme catalyses cross-linking 
between elastin and fibrillar collagen, and is essential for growth and repair of connective 
tissue matrices. 
 
2.2.2 Endothelial effects of homocysteine  
Mild-moderate HHCy is associated with endothelial dysfunction in humans [10,44,109], 
experimental primates[71], and rodents [18,24,59,68,108,122].  
Inhibition of cell proliferation. HCy suppresses cell proliferation in endothelial cells, contrary 
to its proliferative action in vascular myocytes. In preparations of human aortic endothelial 
cells (HAEC), pig aortic endothelial cells and HUVEC, tritiated thymidine incorporation was 
inhibited dose-dependently by modest HCy concentrations (10 to 50 µM; 24hr exposure) 
[119]. The half-maximal concentration for L-HCy was approximately 10 µM in these various 
endothelial preparations, with D,L-homocysteine showing roughly 2-fold lower potency, and 
L-cysteine without effect, indicating a specific action of L-HCy [119].  HCy-treated HAEC 
had greatly increased levels of s adenosyl homocysteine (SAH; which is a potent inhibitor of 
methyl transferase enzyme activity) and reduced carboxyl methylation of p21-ras. Inhibition 
of endothelial proliferation has also been reported at higher HCy concentrations (100 to 1000 
µM) [112].  
At these high concentrations, caspase-dependent cell death is seen (500 - 1000 µM) [69].  
This pro-apoptotic action of high HCy concentration was abrogated by the nitric oxide donor 
SNAP, the antioxidant alpha-tocopherol, or by an antioxidant mixture of superoxide 
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dismutase and catalase [69].  High concentrations of HCy (>200 µM) produced endoplasmic 
reticulum (ER) stress in endothelial cell cultures [89]. 
 
Inhibition of endothelial nitric oxide synthase (eNOS). In cultures of aortic endothelial cells 
from adult mice, moderate concentrations of HCy (range 5 - 200 µM) inhibited eNOS 
activity, evidenced by depressed L-citrulline and nitrite formation [57]. This accords with in 
vivo data showing lower eNOS activity in Cbs null mice relative to wildtype mice, and 
intermediate eNOS activity in Cbs
+/-
 heterozygotes [57]. Similarly, in coronary artery rings 
from adult pigs application of HCy (10 - 100 µM) reduced endothelium-dependent 
vasodilation [11].  Endothelium-independent vasodilation (in response to the NO donor 
nitroprusside) was unaffected, supporting an endothelial action for HCy. Downregulation of 
eNOS expression was also seen in human aortic endothelial cells but only at higher HCy 
concentration (200 µM)[57]. By way of caution, the endothelial preparations in most of these 
studies came from large arteries, and may not entirely reflect microvascular signalling. 
Gene induction effects. Screening for gene induction in endothelial cells following HCy 
exposure revealed several candidates, [65,102]. In microvascular endothelial cells derived 
from mouse brain, treatment with moderate concentrations of HCy (up to 40 μM, 24 hours) 
increased activity of the matrix metalloproteinase MMP-9 concentration-dependently, while 
growth factor synthesis decreased (VEGF, FGFα, leptin) [103]. Over the same HCy 
concentration range, shedding of β1 integrin from the endothelial cell surface was also 
seen[103]. Such effects in intact blood vessels could undermine the extracellular matrix 
integrity in the intimal layers around endothelial cells, and contribute to the anti-proliferative 
effects of HCy in endothelial cells. 
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2.2.3 Homocysteine actions on blood components 
Acute exposure to physiological concentrations of HCy (less than 10 µM) increased the 
affinity and degree of specific binding for fibrin to Lp(a), a complex that includes 
Apolipoprotein-A and shares structural homology with plasminogen [43]. HCy increased 
binding by plasmin-modified fibrin (20 fold) and by native fibrin (4 fold). This may be a 
thiol-dependent action as other small thiol compounds (cysteine, GSH) had a similar effect, 
whereas sulphur containing compounds that lack the free -SH group including methionine 
and SAH had no effect. Low HCy (10 µM) also greatly reduced binding of anti-thrombin III 
to endothelial cells derived from porcine aorta [86]. 
The pro-coagulant effect of modest levels of HHCy was evident in patients with peripheral 
occlusive arterial disease (diagnosed as intermittent claudication). In isolated platelets taken 
from patients with higher plasma HCy (average 19 µM) the inhibitory effect of a nitric oxide 
donor (GSNO, 1 µM) on platelet-fibrinogen binding was 5-fold lower than that of subjects 
with normal HCy (average 11 µM)[95]. In HUVEC cultures, binding of tissue plasminogen 
activator (tPA) to the cell surface was inhibited by high concentrations of HCy (up to 1.5 
mM) [41]. 
 
3. Experimental animal models relevant to elevated homocysteine  
Induction of HHCy in an animal model can be achieved via genetic manipulation or diet.  
Here we outline animal models that have shown HHCy, sufficient to cause cognitive deficits 
and vascular adverse events in the brain. Here we discuss transgenic mouse strains with 
mutations in the genes that underlie severe HHCy in humans (CBS, MTHFR), and animals 
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with diet-induced HHCy. Further information on animal models is given in previous reviews 
[19,58,110]. 
3.1 Cystathionine beta synthase (CBS) converts HCy to cystathionine, which is then 
converted to cysteine, during normal biochemical processing. In humans, deficiencies in CBS 
result in severe HHCy and increased risk of thrombosis, and are the most common cause of 
hereditary HHCy. While homozygous Cbs knockout mice [121] have a neonatal lethal 
phenotype,  inducible Tg-hCBS mice avoid this problem [39]. In Tg-hCBS mice, human CBS 
is under the control of a zinc-inducible promoter. During pregnancy and lactation drinking 
water is supplemented with Zn
2+
 to rescue the neonatal lethal phenotype[120]. At weaning, 
the zinc supplementation is withdrawn and the progeny develop HHCy (plasma HCy 170 
µM, relative to 5 µM in control animals). Another CBS transgenic model reproduces the 
I278T mutation, which is the second most common allele found in CBS-deficient 
patients[66]. Tg-I278T Cbs
-/-
 mice have less than 3% wildtype CBS activity and develop 
HHCy (plasma HCy 290 µM). Tg-I278T Cbs
-/-
 mice also exhibit facial alopecia, osteoporosis, 
ER stress in the liver and kidney, and reduced mean survival, Tg-hCBS mice do not show any 
of these phenotypic changes. Although thrombosis is the most common symptom of CBS 
deficiencies in humans, neither mouse model exhibits any thrombotic or vascular defects.  
Cbs
+/-
 heterozygous mice have a 50% lower CBS activity compared to wildtype mice, and 
develop mild HHCy on normal diet (plasma HCy 6-8 µM) [4,59,121], augmented by high 
methionine diet for 8-20 weeks (plasma HCy ~20 µM)[4].  Cbs
+/-
 heterozygote mice exhibit 
substantial vascular dysfunction. They have thickened arteries, including cerebral arteries, 
with evidence of endothelial damage [4,59]. Cerebral arteriolar walls are 25% thicker in 
Cbs
+/-
 heterozygote mice, relative to WT controls [4]. This was accompanied by mild 
hypertension and blood-brain barrier dysfunction [4]. This vasomotor dysfunction is 
primarily based on endothelial dysfunction, and is largely attributed to redox imbalance and 
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decreased bioavailability of NO. Compared to Cbs
 
null mice, Cbs
+/-
 mice display a milder 
HHCy and may be a more useful model to study hyperhomocysteinemic effects on the 
vasculature.  
3.2 Methylenetetrahydrofolate reductase (MTHFR) is the rate-limiting enzyme in conversion 
of HCy to methionine. In humans, several MTHFR polymorphisms produce HHCy and 
neurological conditions, including progressive demyelinating neuropathy and cognitive 
impairment. MTHFR knockout mice [13] exhibit elevated plasma HCy . Similar to the Cbs 
mouse model, MTHFR
+/-
 heterozygotes exhibit mild HHCy (plasma HCy ~20 μM, relative to 
3-5 μM in wildtype littermates)[80] and appear outwardly healthy, while MTHFR-/- 
homozygotes (plasma HCy 31-33 µM, relative to 3 µM in WT animals) survive poorly and 
present with motor and gait abnormalities within 5 weeks after birth. MTHFR
+/-
 mice exhibit 
some loss of function in cerebral vessels [85] and high intramural collagen in peripheral 
arteries [85]. MTHFR
-/-
 homozygotes also present with abnormal lipid deposition in the aorta 
and disruption of the laminar structure of the cerebellum (though with no obvious changes in 
the cerebral cortex or cerebrum).  
3.3 Dietary induction of HHCy in mice and rats can be achieved through either a reduction in 
vitamins B6, B9 and B12, or by diets supplemented with HCy  or methionine 
[4,18,68,108,111]. Vascular dysfunction has been reported in primates (Cynomolgus 
monkeys) following diet-induced mild-moderate HHCy (plasma HCy 11 µM, relative to 4 
µM on normal diet) [70,71].  (Earlier studies in baboons employed direct infusion of HCy 
[42]). Responses of resistance vessels to endothelium-dependent vasodilators were markedly 
impaired in HHCy monkeys, and anticoagulant thrombomodulin activity in the aorta 
decreased by 34 % [71].   
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Vitamins B6, B9 and B12 act as essential cofactors for the conversion of HCy to methionine 
or cysteine, combined with enrichment in dietary methionine, causes an increase in 
conversion to HCy.  In 6-month-old rats fed a folate-deficient diet for 8 weeks, increased 
plasma HCy (increased from 6 µM to 19 µM) was accompanied by ultrastructural changes to 
cerebral capillaries, endothelial damage, swelling of pericytes, basement membrane 
thickening and fibrosis [63].  Rats fed a diet high in HCy for 5 or 15 months (plasma HCy 26 
µM at both time-points, relative to 10 µM in controls) both showed cognitive impairments, 
decreased acetylcholine in the brain and cortical micro-hemorrhages[91]. In wild-type mice 
fed a B-vitamin deficient diet, cognitive deficits resulted from relatively-brief (10 week) diet-
derived mild HHCy (plasma HCy 35 µM, relative to 5 µM on normal diet) [111]. The authors 
found a decline in spatial learning (water maze task) accompanied by rarefaction of 
hippocampal blood vessels and of microglia [111]. Aged Tg2576 mice on HCy-elevating diet 
(plasma HCy 27 µM, relative to 5 µM in controls) also showed deficits in spatial reference 
memory, but not working memory tasks (delayed non-match to position)[5].  
Plasma HCy levels were also increased in 3-month-old mice that were fed a diet deficient in 
vitamins B6, B9 and B12 and also enriched in methionine for 3 months [108]. These mice 
exhibited cognitive impairments on the two-day radial arm water maze, cerebral 
microhemorrhages and increased MMP2 and MMP9 activity. This dietary model results in 
plasma HCy in the range 70-90 µM [108]. While these concentrations are higher than most 
human subjects classified under mild-moderate HHCy, this level is classified as moderate 
HHCy in mice [29]. 
 
4. Overview of clinical interventional trials relevant to stroke and dementia  
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If the hypothesis that HHCy causes cognitive decline is correct, then lowering plasma HCy 
concentrations (e.g. by B vitamin supplementation) should slow cognitive decline and 
possibly prevent dementia. Multiple clinical trials have tested B vitamin administration (folic 
acid, vitamins B6 and B12) with a cognitive endpoint. There have been three meta-analyses of 
these intervention trials [15,33,118].  
 
4.1 Meta-analyses of clinical trials.  
Three meta-analyses [15,33,118] will be considered here, with respect to the following 
important features related to trial design [78].  
i) The hypothesis being tested. If the hypothesis is that treatment slows cognitive 
decline, then the placebo group must exhibit cognitive decline. Unless the placebo 
group declines, the trial can only show whether the treatment enhances or worsens 
cognition. 
ii) Age range of the test cohort. If cognitive decline is the outcome, the age of the 
subjects should be in the range where cognitive decline occurs.  
iii) Trial duration. Is this sufficient to observe cognitive decline? In cognitively healthy 
elderly people, MMSE declines by only about 0.1 points per year on average. 
iv) The instrument used to assess a treatment effect. Is the instrument sensitive enough to 
detect change over the period of the trial? The instrument may display ceiling or floor 
effects, which limit the detectable effect size. Points (ii), (iii) and (iv) will together 
dictate whether the trial has sufficient power to detect a real effect.  
v) Is the intervention appropriate? For B vitamins, the daily doses should be sufficient to 
lower plasma HCy by at least 20%. 
vi) Is the group likely to respond to intervention? A B-vitamin supplement will produce 
no effect if the participants already have adequate B vitamin status. Such trials should 
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be limited either to subjects with high plasma HCy or insufficient B vitamin function. 
Alternatively, subgroup analyses should be performed to stratify for baseline values of 
B vitamins and plasma HCy.  
 
The majority of the 26 trials analysed in the three meta-analyses [15,33,118]  did not fulfil 
these requirements. Furthermore, by combining data from different trials (e.g. by using 
standardised mean differences) the meta-analyses have neutralised some of these 
requirements, even though they were fulfilled in individual trials. These three meta-analyses 
[15,33,118]  have recently been appraised by others [78] and are outlined below. 
 
In one analysis 7 of the 9 trials were of short duration (≤ 12 months; the two shortest lasted 1 
month) with an overall median duration of 6 months [118]. In the trial with the largest 
number of participants (n=910), which accordingly was given a strong weighting, the doses 
of folic acid (0.2 mg) and vitamin B12 (1 µg) were too low to influence plasma HCy. In a 
trial where the doses of vitamins were adequate [79], there was no significant cognitive 
decline in the placebo group (mean MMSE 29.17 at baseline, 29.32 after 2 y). Thus, the 
conclusion that folic acid has no effect on the prevention of age-related cognitive decline 
[118] may be false. The authors concluded that longer trials of folate supplementation are 
needed, with larger cohorts and with cognitive decline and dementia as outcomes [118]. 
 
A larger meta-analysis combined 19 trials (n= 5,398 participants) [33]  of which 8 were in the 
previous analysis [118]. In this analysis, only 6 of the trials (n=785 participants) were 
performed on subjects with cognitive impairment and the results were reported separately for 
this group and for participants without cognitive impairment. This study concluded “It 
remains to be established whether chronic treatment with B-vitamins is associated with better 
25 
 
cognitive outcomes, or if their use could reduce the risk of dementia in later life” [33].  This 
meta-analysis also suffered from lack of statistical power to detect differences associated with 
small effect sizes (<0.2) between the supplemented and placebo groups. Another limitation is 
that the analysis combined data from 62 different cognitive tests, by converting the individual 
test scores to standard deviation scores, in order to compute standardised mean differences. 
Thus, there was considerable clinical heterogeneity in the combined data. In order to analyse 
the data, the authors assumed zero correlation between the assessments at baseline and study 
endpoint. This may be a serious limitation, as baseline cognitive test performance is a well-
known predictor of later test performance. Thus, in any analysis of cognitive decline it is 
imperative to use a model that controls for the baseline value (which is not possible with the 
widely-used standardised mean difference method). A further limitation of this method is that 
it depends upon the t test and so the analysis cannot be adjusted for important co-variates 
(e.g. gender and education) that are known to influence cognitive change.  
 
A third meta-analysis[15] aimed to test the effect of lowering plasma HCy on ‘cognitive 
ageing’ (though this was not defined). The analysis considered 11 trials (n=22,000) of which 
5 had been included in one or both of the previous two studies, and concluded “B-vitamin 
supplementation caused HCy-lowering but was without significant effect on cognitive 
function or cognitive aging”[15]. Trials on subjects with a prior diagnosis of cognitive 
impairment or dementia were specifically excluded[15]. Furthermore, in most subjects in the 
included trials, cognitive decline could not be measured since baseline global cognitive 
measures were not available for 76% of subjects. It is therefore unclear what can be 
concluded from such trials, apart from a lack of a cognitive enhancing (or a harmful) effect of 
B vitamins.  
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4.2 The FACIT and WAFACS trials 
 
Two of the trials (n=2,825) that were included in the above meta-analyses did report 
cognitive scores at baseline. Both these trials showed significant effects of B vitamins on 
cognitive change in those subjects with high plasma HCy [23], or with poor B vitamin status 
[60]. The FACIT trial (n=818; mean age 60 y) recruited people from the Netherlands with 
plasma HCy was between 13 and 26 µM, but with adequate vitamin B12 status[23]. Folic 
acid (0.8 mg/day) was administered for 3 y. At the end of the trial plasma HCy concentration 
was 26% lower than in the placebo group. The trial assessed several cognitive domains and 
found that performance on sensorimotor speed, information processing speed, and complex 
speed had all declined in the placebo group after 3 y but that the decline was slowed by folic 
acid treatment. There was an improvement in memory performance in the placebo group 
(likely due to learning effect) but a greater degree of improvement occurred in the folic acid 
group. Global cognitive performance also improved more in the folic acid group. Notably, 
there was a larger beneficial effect of folic acid on information processing speed in those 
whose base-line plasma HCy was above the median than in those below the median. The 
authors estimated that folic acid treatment conferred cognitive performance of someone 4.7 y 
younger for memory, 1.7 y younger for sensorimotor speed, 2.1 y younger for information 
processing speed, and 1.5 y younger for global cognitive function. Overall, this trial was 
consistent with the view that lowering plasma HCy slows decline in those cognitive domains 
that are sensitive to ageing[23]. 
 
In the US-based WAFACS trial (n=5442, all female, age >40y) a daily combination of B 
vitamins (2.5 mg folate, 50 mg B6, 1 mg B12) was tested for secondary prevention of 
cardiovascular disease [60]. Cognitive testing was carried out in a substudy (n=2009, 
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age>65y). While cognitive change from baseline did not differ between the vitamin-treated 
and placebo groups in the cohort as a whole, there was a significant protective effect in those 
participants with low baseline dietary intake of folate [60]. 
 
4.3 The VITACOG trial  
 
VITACOG was designed to test whether lowering plasma HCy would slow the accelerated 
rate of brain atrophy that occurs in people with MCI [106]. Volunteers (n = 168) with MCI 
were randomized to placebo or a daily combination of folic acid (0.8 mg), vitamin B12 (0.5 
mg) and vitamin B6 (20 mg) for two years. Volumetric MRI scans were performed at the 
start and end of the trial. B vitamin treatment led to a highly significant slowing in the rate of 
global brain atrophy (average 30%). The effect of B vitamin treatment depended on baseline 
plasma HCy, with a 53% slowing of atrophy in those in the top quartile (> 13 µM)[106]. 
 
A further analysis of the MRI scans from VITACOG subjects revealed strong effects of B 
vitamin treatment on regional brain atrophy in MCI [22]. There was 7-fold less regional brain 
atrophy in the B vitamin group compared with the placebo group, though this effect was 
significant only in people with plasma HCy above the median. The gray matter regions 
protected by B vitamin treatment included: structures of the medial temporal lobe, the 
precuneus, angular gyrus and supramarginal gyrus, all regions known to be vulnerable to the 
AD disease process. It was concluded that the B vitamin treatment had slowed the atrophy of 
AD-related regions of the brain, in people with raised plasma HCy [22]. 
 
VITACOG was not powered to detect any effect of homocysteine-lowering on cognition. 
Nevertheless, a pre-specified analysis stratifying for plasma HCy showed that in people with 
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baseline plasma HCy above the median (11.3 µM), cognitive decline was virtually prevented 
in the following domains: episodic memory, semantic memory and global cognition (MMSE) 
[20].  
 
4.4 Importance of initial homocysteine concentration.  
The VITACOG trial implies a threshold effect of plasma HCy on biological outcomes such as 
brain atrophy and cognition. Slowing of brain atrophy and of cognitive decline occurred only 
in people with plasma HCy > 11 µM, while improvement in clinical measures was only 
found with plasma HCy > 13 µM. These findings are consistent with previous observations. 
For example, there is a concentration-related (> 10 µM) association of plasma HCy with 
incidence of dementia. In the OPTIMA study, only concentrations above 11 µM were 
associated with an increased rate of atrophy of the medial temporal lobe[16]. At 
concentrations  > 10 µM there was a concentration-dependent increase in the rate of cognitive 
decline in AD patients under 75 y [88]. If the threshold for effects of plasma HCy is about 
10-11 µM that could explain why some studies, for example in countries that already employ 
mandatory folic acid fortification, do not find associations of plasma HCy with cognitive or 
brain outcomes. Thus, an 18-month trial of high-dose B vitamins in patients with AD in the 
USA (baseline plasma HCy 9.16 µM) did not find an overall effect of treatment on cognitive 
decline[1]. It should be noted that those patients with mild AD did show a protective effect of 
B vitamins after 15 months, which may indicate that timing of HCy-lowering intervention is 
critical. 
 
4.5 Interactions with other risk factors.  
Retrospective analysis of the VITACOG data revealed an interaction with omega-3 fatty 
acids. It emerged that the protective effect of B vitamin treatment on both brain atrophy and 
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cognitive decline in MCI only occurred in those participants with a good status of long-chain 
omega-3 fatty acids [55]. We also observed that the beneficial effect of B vitamins on brain 
atrophy was absent in subjects taking aspirin [106]. These results emphasize the importance 
of considering risk factor interactions. This may be a reason why some trials of B vitamins 
have failed, if the treated population were taking aspirin regularly, as in many trials included 
in the meta-analysis by Clarke et al.[15], or had a poor omega-3 fatty acid status. Further 
trials are needed to test B vitamins in combination with omega-3 fatty acids, in people not 
taking regular aspirin. 
 
4.6 Future trials of B vitamin supplementation for HHCy lowering 
In our view further trails of combined B vitamin supplementation are called for. These should 
incorporate the lessons from previous trails, and from recent experimental work. In order to 
maximise likelihood of treatment effect, future trials should aim to target individuals who are 
in the at-risk age range, but not demented. Cohorts with inadequate baseline B vitamin status 
should be targeted, and a full combination supplement (B6, B12 and folate) supplied at high 
dose. With the benefit of extant trial data, accurate power analyses should be possible, to 
allow conservative design in terms of sufficient cohort size and treatment duration.  
 
A possible scenario could be a government-sponsored scheme within areas of social 
deprivation, where long-term vitamin inadequacy is prevalent. Participants would be 
randomised to a highly-flavoured tablet formulation, such as a vitamin C preparation, without 
B vitamins (placebo) or with a substantial dose of B6/B12/folate (treatment). Recruitment 
would be offered to all older persons in a public setting. Recruitment, registration and supply 
would be at a routine public forum, such as weekly pension collection, or GP drop-in clinics 
for cardiovascular monitoring. 
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For a future trial in VCID, suitable endpoints may be MRI-derived measures of disease 
progression [99]. Such surrogate biomarkers may be of utility in trials for VCID for two main 
reasons. First, a large proportion of individuals who exhibit VCID and VCID biomarkers will 
not convert to dementia. Second, MRI-based endpoints will permit a test of efficacy in a 
smaller cohort than would be required to detect a difference in cognitive decline.   
 
4.7 Preclinical studies lowering Hcy levels.  
While no animal studies have been done to lower Hcy levels and test cognition or 
neuropathology, some animal studies have been done with the aim of studying cardiovascular 
effects of Hcy lowering. One study used the CBS-/- genetic model, induced 
hypercholesterolemia, and then targeted CBS expression using a viral vector to restore low 
Hcy levels. Using this approach, the investigators found that the restoration of low Hcy levels 
improved infarct healing and attenuated remodelling after a myocardial infarction [83]. The 
same group used the same genetic approach in a model of pressure overload-induced 
cardiomyopathy and found that Hcy lowering reduced mortality and lowered oxidative stress 
[84]. A few studies have examined the effects of various B-vitamins, the most common being 
folic acid, on learning and memory, however, these studies did not examine homocysteine 
levels [8,12]. 
 
5. Conclusions 
The molecular targets of HCy that are relevant to VCID are not fully defined. While 
numerous biochemical and cellular actions have been reported, on inspection most resulted 
from HCy concentrations above the clinically relevant range of 10-100 µM. Reported actions 
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of HCy below 100 µM were primarily vascular. These included: PKC activation and 
proliferation of vascular myocytes; vessel wall fibrosis and collagenosis; reduced 
proliferation and suppression of nitric oxide signalling in endothelial cells; heightened 
superoxide formation, and release of inflammatory mediators (MCP-1, IL-6, IL-8, MMP9); 
various pro-coagulant actions on different blood components (fibrinogen, ApoA, 
antithrombin-III). Mouse models of HHcy and the extensive body of epidemiology data 
indicate a strong relationship between HHcy and cognition. Further, it is clear from the 
mouse studies that HHcy can influence AD pathology, a further consideration for clinical 
studies. Future studies are clearly required to fully characterize and identify the key 
molecular pathways linking Hcy to VCID.  
 
At least 19 clinical trials relevant to VCID have tested HCy-lowering interventions. Many  
were compromised by the challenges of performing a cognitive clinical trial (trial duration, 
statistical power, cohort age, B vitamin status). Three trials supported a beneficial effect 
(FACIT, WAFACS, VITACOG). The question as to whether or not lowering plasma HCy 
slows cognitive decline requires further well-designed trials. The extensive clinical and 
preclinical data strongly support Hcy as a key mediator for VCID. The challenge is now to 
design clinical studies that fully address this link. Preclinical animal model studies will be 
essential for the identification of the appropriate time-points when Hcy effects can be 
manipulated and reversed.  
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Figure Legend 
Figure 1. Biochemical Pathways linking homocysteine and B vitamins. 
Methionine is converted to homocysteine by methylation and subsequent hydrolysis. 
Homocysteine is then either cycled back to methionine via the folate cycle, catalysed by  
methylenetetrahydrofolate reductase (MTHFR) and the essential cofactor vitamin B12. 
Alternatively homocysteine can be further metabolized to cysteine via cystathionine beta 
synthase (CBS) and the essential cofactor vitamin B6. Homocysteine conversion to cysteine 
occurs primarily in the liver. All other reactions are ubiquitous. For further details on HCy 
biochemistry, see [52,115].  SAM, S-adenosyl methionine; SAH, S-adenosyl homocysteine.  
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Effects observed 
Effective 
concentration 
Species Reference 
Inhibition of low affinity PMB-
TBOA [blocks high affinity 
excitatory NT transporters] 
insensitive D-aspartate uptake in 
astrocytes 
5mM Rat 
(Holten et al., 
2008) 
 
Neurite loss and size reduction 
>100m after 48 h Rat 
(Heider, 
Lehmensiek, 
Lenk, Muller, & 
Storch, 2004) 
KYNA and KAT activity inhibition 
IC50 
KYNA= 
 3.93mM 
KAT= 
5.0mM 
Rat 
(Kocki et al., 
2003) 
Inhibition of neural network 
activity (spontaneous spike rate) 
IC50 
1.3M 
 
Rat 
(Görtz et al., 
2004) 
Hippocampal (CA1) & cortical 
culture toxicity (death) w/ short 
and long incubation 
 
Short incubation 
 50M (cort. tox) 
100M (hippo. tox) 
 
Long incubation (48hrs) 
All tox at 5mM 
Rat 
 
(Flott-Rahmel 
et al., 1998) 
Excitatory currents in granular 
and purkinje cells 
50M Chicken 
(Kataoka, 
1996) 
Agonism of mGluR4a currents 
and inhibition of lateral perforant 
pathway neurons 
 
EC50 for inhibition of 
mGluR4a inhibition of 
cAMP: 49M 
 
IC50 for inhibition of 
lateral perforant 
pathway depolarisation 
[electrode stimulated]: 
400M 
 
Hamster 
(Johansen et 
al., 1995) 
IP3 formation + NMDA agonism 
In cerebellar granule cells 
 
EC50: 117M 
 
Cell 
culture 
(Gorman & 
Griffiths, 1994) 
Release of D-aspartate 
(exogenous) & Activation of 
excitatory NTR in cerebellar 
granule cells 
 
500 M 
Cell 
culture 
(Dunlop & 
Grieve, 1992) 
NMDA and AMPA steady state EC50 Cell (Curras & 
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inward current production NMDA: 13M 
AMPA: 430M 
 
culture Dingledine, 
1991) 
Neuronal death 50M 
Cell 
culture 
(Eimerl & 
Schramm, 
1991) 
Cell death 
Neurotoxicity 
1000M 
Cell 
culture 
(Murphy, 
Schnaar, 
Coyle, & 
Johns, 1990) 
Glycine antagonism at NMDA 100M Rat 
(Mcdonald, 
1990) 
Agonism of NMDA coupled to 
[3H]GABA release in striatum . 
Measured via increases in GABA 
conc over 3min depolarisation 
period 
EC50: 36M Mouse (Weiss, 1990) 
NA release from hippocampal 
neurones 
2mmol/L Rat 
(Wu, Vezzani, 
& Samanin, 
1989) 
High affinity L-Glu transporter 
inhibition in synaptosomes, 
neurons and astrocytes (from 
mice) 
Synaptosomes: 
5000M,  
Neurons: 
2500M 
Astrocytes: 
1250M 
Mouse 
(R Griffiths et 
al., 1989) 
Neurotoxicity & 
Neuronal death 
ED50 
40M 
Mouse 
(Kim, Koh, & 
Choi, 1987) 
Inhibition of [(3)H]l-glutamate 
uptake in astrocytes 
1mM 
Rat & 
mouse 
(Balcar, 
Schousboe, 
Spoerri, & 
Wolff, 1987) 
Displacement GABA-mimetic 
[3H]muscimol from specific, high-
affinity sites 
Ki(apparent) 
4800 microM 
Cow 
(Egbuta & 
Griffiths, 1987) 
1. Receptor binding assays: 
NMDA, AMPA & katinate 
2. Sodium flux through NMDA 
3. Excitotoxicty in retinas on 
histopath eval 
1. NMDA= 3.3M, 
Katinate=110M, 
AMPA=20M 
2. Potency: 1.4M 
3. Lowest effective 
dose: 200M 
Rat & 
Chicken 
(Pullan et al., 
1987) 
Inhibition of high affinity 
taurine uptake in to 
astrocytes  
 
IC50: 1.5mM 
 
Rat 
(Allen, 
Schousboe, & 
Griffiths, 1986) 
Displacement at excitatory amino 
acid receptors 
Ki (M) 
D,L-HCA: 45.9  
D-HCA: 64.2 
L-HCA: 38.7 
Snail & 
rat 
(Pin, Bockaert, 
& Recasens, 
1986) 
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